Table 2.
Demographic characteristics, clinical symptoms, and anatomical variants of the study subjects according to the new and standard classifications for extrahepatic bile duct
| New classification for EHBD | Standard classification for EHBD | |||||||
|---|---|---|---|---|---|---|---|---|
| Type 1 (ratio CDDP/EHBD ≤ 50%) | Type 2 (ratio CDDP/EHBD > 50% and ≤ 75%) | Type 3 (ratio CDDP/EHBD > 75%) | P | Type 1 (ratio CDDP/EHBD ≤ 33%) | Type 2 (ratio CDDP/EHBD > 33% and ≤ 66%) | Type 3 (ratio CDDP/EHBD > 66%) | P | |
| N of patients | 181 | 675 | 148 | - | 36 | 549 | 423 | - |
| Gender (M) | 87 (48) | 322 (47.7) | 52 (35) | 0.017 | 14 (38.9) | 270 (49.5) | 177 (41.8) | 0.040 |
| Age (years) | 64 (52–75) | 64 (51–72) | 59.5 (49–71) | 0.049 | 62.5 (51–75.5) | 64 (52–73) | 61 (50–72) | 0.301 |
| Previous cholecystectomy | 37 (20.4) | 130 (19.3) | 20 (13.5) | 0.210 | 5 (13.9) | 115 (21.1) | 67 (15.8) | 0.086 |
| Intra-hepatic biliary variants4 | 0.126 | 0.065 | ||||||
| Type 1 | 98 (54.1) | 438 (64.9) | 99 (66.9) | 16 (44.4) | 335 (61.4) | 284 (67.1) | ||
| Type 2 | 35 (19.3) | 99 (14.7) | 18 (12.2) | 7 (19.5) | 92 (16.9) | 53 (12.5) | ||
| Type 3a | 39 (21.6) | 101 (15) | 23 (15.5) | 10 (27.8) | 92 (16.9) | 61 (14.4) | ||
| Type 3b | 9 (5) | 37 (5.5) | 8 (5.4) | 3 (8.3) | 26 (4.8) | 25 (5.9) | ||
| CDDP length (mm) | 31 (25–36) | 49 (43–56) | 62 (53.5–70) | < 0.001 | 21 (16–25) | 43 (36–49) | 57 (50–64) | < 0.001 |
| EHBD length (mm) | 76 (66–85) | 77 (68–85) | 75 (67–86) | 0.467 | 75 (64.5–83) | 76 (68–85) | 77 (69–86) | 0.270 |
| CD radial insertion in the EHBD | < 0.001 | < 0.001 | ||||||
| Lateral | 66 (36.5) | 559 (82.8) | 139 (93.2) | 3 (8.3) | 377 (69.2) | 384 (90.9) | ||
| Posterior | 21 (11.6) | 86 (12.7) | 5 (3.4) | 3 (8.3) | 81 (14.9) | 28 (6.6) | ||
| Medial | 94 (51.9) | 30 (4.4) | 4 (2.7) | 30 (83.4) | 87 (15.9) | 11 (2.5) | ||
| Intra-pancreatic CD | 117 (64.6) | 32 (4.7) | 1 (0.7) | < 0.001 | 33 (91.7) | 111 (20.4) | 6 (1.4) | < 0.001 |
| MRCP findings | ||||||||
| Choledochal lithiasis | 19 (19) | 36 (10.8) | 8 (12.5) | 0.097 | 3 (16.7) | 39 (13.9) | 21 (10.6) | 0.480 |
| Gallstones | 35 (35) | 131 (39.3) | 23 (35.9) | 0.687 | 7 (38.9) | 102 (36.4) | 80 (40.2) | 0.702 |
| IPMN | 40 (42.1) | 192 (50.4) | 45 (54.2) | 0.230 | 10 (52.6) | 145 (46.9) | 122 (52.8) | 0.385 |
| PSC | 23 (29.5) | 115 (37.8) | 30 (44.1) | 0.181 | 5 (35.7) | 84 (33.9) | 79 (42) | 0.217 |
| Pancreatic a/o biliary cancers | 18 (24.7) | 35 (15.6) | 9 (19.2) | 0.214 | 3 (25) | 36 (18) | 23 (17.4) | 0.808 |
CDDP, cystic duct to duodenal papilla; EHBD, extrahepatic bile duct; CD, cystic duct; MRCP, magnetic resonance cholangiopancreatography; IPMN, intraductal papillary mucinous neoplasia; PSC, primary sclerosing cholangitis; a/o, and/or